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Cyclosporin A and verapamil have different effects on energy metabolism
in multidrug-resistant tumour cells
H.J. Broxterman, H.M. Pinedo, G.J. Schuurhuis & J. Lankelma
Department ofMedical Oncology, Free University Hospital, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Summary Cyclosporin A (SandimmuneO) rapidly induced an increase in daunorubicin accumulation in
multidrug-resistant human ovarian carcinoma cells (2780AD) and was more potent than verapamil. Steady-
state 3H-cyclosporin A accumulation at 37'C in 2780AD cells was 60-70% of that in the sensitive A2780 cells.
A rapid increase of ATP consumption and lactate production was induced in 2780AD cells by verapamil, but
not by cyclosporin A. These results suggest that the interactions of cyclosporin A and verapamil with
P-glycoprotein, which leads to inhibition of drug transport, have a different mechanistic basis.
The development of resistance of tumour cells to a wide
range of natural product derived anticancer agents is
generally called multidrug resistance. One type of multidrug
resistance is characterised by an increased energy-dependent
outward cellular transport of the anti-cancer drugs (Peterson
et al., 1980; Skovsgaard & Nissen, 1982; Inaba & Johnson,
1978). This transport is related to overexpression of a plas-
mamembrane glycoprotein, termed P-glycoprotein (Bradley
et al., 1988), which has been shown to have ATPase activity
(Hamada & Tsuruo, 1988). The discovery of this drug export
system has triggered research to find drugs which specifically
would block its activity, since such drugs might be potentially
useful to increase the efficacy of chemotherapy. A number of
classes of compounds, which increase the accumulation of
cytostatic drugs, such as anthracyclines and vinca alkaloids,
in P-glycoprotein expressing cell lines, have now been
identified (Helson, 1984; Kessel, 1986; Schuurhuis et al.,
1987). Specific binding of such drugs to P-glycoprotein (Safa
et al., 1987), stimulation of ATPase activity of P-glycoprotein
(Hamada & Tsuruo, 1988) and increase of ATP hydrolysis in
multidrug resistant cells (Broxterman et al., 1988b) by such
drugs has been shown. However, the exact molecular
mechanism of action of these drugs has not been elucidated
(Huet & Robert, 1988; Gruber et al., 1988) nor is it known
whether they all act via the same mechanism (Akiyama et al.,
1988). Structure-activity relationships are now being deter-
mined for these drugs (Zamora et al., 1988; Ramu & Ramu,
1989).
Recently it has been found that the immunosuppressant
drug cyclosporin A is able to reverse P-glycoprotein-
dependent multidrug resistance (Slater et al., 1986; Osieka et
al., 1986; Twentyman et al., 1987; Twentyman, 1988;
Vayuvegula et al., 1988), but the mechanism by which cyclo-
sporins modulate the sensitivity to chemotherapeutic agents
has not been elucidated (Chambers et al., 1989). In order to
delineate further the mechanism ofaction ofcyclosporin A as
a resistance modifier we compared its effect with verapamil
on daunorubicin accumulation and energy metabolism in
multidrug-resistant cells and found evidence that these agents




Verapamil hydrochloride was from Sigma (St Louis, MO,
USA) and daunorubicin hydrochloride was from Specia
(Paris, France). Sandimmunee, which is cyclosporin A,
dissolved in cremophor EL/ethanol and pure cyclosporin A
(which we dissolved in ethanol) were gifts from Sandoz
(Basle, Switzerland). 14-'4C-daunorubicin (spec. act. 45 Ci
mol-') and [Mebmt-p-3H]-cyclosporin A (10.5 Cimmol-')
were from Amersham (UK).
Cells
Human ovarian carcinoma cells A2780 and' 2780AD and
culture conditions have been described (Rogan et al., 1984;
Broxterman et al., 1987). 2780AD cells were cultured in the
presence of 2 gM doxorubicin (Adriablastina, Farmitalia
Carlo Erba, Milan, Italy) until 4-7 days before experiments.
Drug accumulation experiments
Cellular steady-state accumulation of '4C-daunorubicin and
3H-cyclosporin A was determined by incubation of cells in
complete growth medium, including 10% fetal calf serum
and buffered by 20 mM Hepes, pH 7.45. After incubation
cells were washed twice in ice-cold phosphate buffered saline
and cell-associated radioactivity was determined with liquid
scintillation counting (Broxterman et al., 1987). Values are
expressed as pmol per cell associated drug per 106 cells after
correction for 0°C direct binding to the cells.
ATP and ADP measurements
Ribonucleoside di- and triphosphates were measured in cel-
lular trichloroacetic acid extracts with an ion exchange high-
performance liquid chromatography system (Leyva et al.,
1982). Cells were incubated with verapamil, cyclosporin A or
vehicle in complete medium (medium A) or medium without
glucose but with 10% fetal calf serum and 10 mM sodium
azide (medium B) (Broxterman et al., 1988b). Cellular lactate
formation was measured as described (Broxterman et al.,
1989).
Results and discussion
We first examined the potency of cyclosporin A (Sandim-
mune) to induce an increase in daunorubicin accumulation in
2780AD cells, because such an effect has been reported
(Nooter et al., 1989), while others have found no evidence for
correction of daunorubicin accumulation in multidrug resis-
tant cells (Vayuvegula et al., 1988). As shown in Figure 1,
Sandimmune is a more potent inducer of daunorubicin
accumulation than verapamil in 2780AD cells: e.g. 2ItM
Sandimmune had a similar effect as 8 gtM verapamil, while
8 &M Sandimmune was more potent than 8 ;tM verapamil
(Table I). Since we found that the vehicle Cremophor EL
when used in the same concentration as present in a 2ytM
Sandimmune solution (i.e. 0.003% vol./vol. or 33figml-')
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Figure 1 Effect of cyclosporin A (Sandimmune) on daunorubicin
accumulation in 2780AD cells. Cells were incubated with 1 tLM
daunorubicin for 60 min at 37°C in complete medium, pH = 7.45.
Results are from two experiments, mean ± s.d.
Table I Daunorubicin accumulation in 2780AD cells
Drug (4M) Accumulation (pmolper 106 cells)
19±3
+ verapamil (8) 113±2
+ Sandimmune (8) 241 ±9
+ cyclosporin A (8) 325(n = 1)
About 200,000 cells were incubated (60 min, 37C) in 550 gI medium
A with 1 ^IM '4C-daunorubicin. Data are means±s.d. of three
experiments, each performed in quadruplicate.
itself caused a small, but significant increase of daunorubicin
accumulation in 2780AD cells, we have checked in a separate
experiment that 8tiM cyclosporin A (dissolved in ethanol)
had a similar effect as 8 jsM Sandimmune (Table I). The
effects of Cremophor EL on doxorubicin and vincristine
cytotoxicity in multidrug resistant cells have been further
analysed (Schuurhuis et al., submitted).
Since 2780AD is a typical multidrug resistant cell line, in
which the defect of daunorubicin transport is related to
overexpression of the mdrl gene (Van der Bliek et al., 1988;
Broxterman et al., 1988a), cyclosporin A apparently is a
potent modulator of P-glycoprotein mediated drug transport.
A number of agents that reverse multidrug resistance have
been suggested to interact competitively with antitumour
agents such as the vinca alkaloids for the P-glycoprotein
associated transport mechanism (Horio et al., 1988).
Therefore, to find evidence for P-glycoprotein dependent
transport of cyclosporin A itself, we measured the accumula-
tion of cyclosporin A in A2780 and 2780AD cells and found
(Table II) that the accumulation of 3H-cyclosporin A in
2780AD cells was 60-70% of that in A2780 cells. Although,
the solubiliser Cremophor EL tended to cause a higher cyclo-
sporin A accumulation in both cell types, a difference in
accumulation between parent and resistant cells was present,
whether Cremophor EL was present in the medium (in Sand-
immune) or not, although in the latter case no statistical
significance was reached (Table II). We found similar
accumulation differences for AUXB1 and CHrC5 cells,
another couple of sensitive and multidrug resistant cells (not
shown). These data, together with the recent finding that
cyclosporin A binds specifically to P-glycoprotein (Safa et al.,
1989; Foxwell et al., 1989) would suggest that cyclosporin A
itself is a substrate for the P-glycoprotein related transport
mechanism.
Table II Cyclosporin A accumulation in 2780 cells
Accumulation (pmolper 106 cells)
Drug A2780 2780AD
Sandimmune 88± 17 56± 7a
Cyclosporin A 46± 8 33±6b
About 1,000,000 cells were incubated in medium A at 37°C with
3H-cylcosporinA,dilutedwithSandimmune® orcyclosporinA(stockin
ethanol) to 2lM cyclosporin A finalconcentration. From time-curves it
appeared that a steady-state was reached in 2 min incubation. Data are
from 60 min incubations, means±s.d. from 5 (Sandimmune) or 2
(cyclosporin A) separate experiments. ap<0.01; bp> 0.05, compared
to A2780 (Student's t test). In three experiments the effect of 16tiM
verapamil on cyclosporin A accumulation in 2780AD cells was
measured; a small increase (122± 13% ofcontrols) was measured.
We did find a small effect of 16 1tM verapamil on the
accumulation ofcyclosporin A in 2780AD cells (legend Table
II), while it had a large effect on daunorubicin accumulation
in 2780AD cells (Figure 1). Goldberg et al. (1988) found a
more pronounced effect of verapamil on cyclosporin A
accumulation in CHRC5 cells at a higher verapamil/cyclo-
sporin concentration ratio than we used. Therefore some
interaction between these drugs at P-glycoprotein level may
still be present.
To delineate further the mechanism of reversal of resis-
tance by cyclosporin A we investigated the effect of the drug
on energy metabolism in 2780 cells. We have previously
shown that resistance modifiers such as verapamil, bepridil,
trifluoperazine and diltiazem under appropriate conditions
can decrease the ATP/ADP ratio in P-glycoprotein over-
expressing cells (Broxterman et al., 1988b), and in addition
we showed that the same compounds induced a specific
increase in lactate formation rate in multidrug-resistant,
but not in sensitive cells (Broxterman et al., 1989). Together
with data showing that these drugs are potent inhibitors of
ATP-dependent vinblastine binding and transport in P-glyco-
protein containing plasmamembrane vesicles (Horio et al.,
1988), these results suggested that resistance modifying
agents themselves may be transported by the P-glycoprotein
dependent pump system. Table III, however, shows that
4^.M (and 8 ,sM, not shown) Sandimmune, which more
effectively reversed daunorubicin accumulation than 8 ytM
verapamil (Figure 1), did not affect the ATP/ADP ratio in
2780AD cells, while 8 ItM verapamil decreased this ratio to
48%. In a separate experiment we have checked that the
onset of cyclosporin's effect on daunorubicin accumulation
was very rapid, that is within 2.5 min. Furthermore a steady-
state accumulation of cyclosporin A was already reached in
2 min (legend of Table II). Thus if a transport-related energy
effect of cyclosporin A would be present, it should have a
rapid onset too. Furthermore we found that cyclosporin A in
contrast to verapamil (Broxterman et al., 1989), did not
induce an increase in glycolysis during 60 min of drug expo-
sure in three multidrug resistant cell lines, 2780AD (Table
IV), H134AD and MCF-7/AdrR (not shown). A small effect
of cremophor EL on lactate formation was seen in A2780
only.
In conclusion, we present evidence that cyclosporin A is a
very effective inhibitor of the P-glycoprotein related dauno-




Drug ("M) A2780 2780AD
Verapamil 8 98±ll%a 48±10%
Sandimmune 4 98± 16% 97± 6%
Cells were incubated in medium with sodium azide (medium B, as
described in Broxterman et al., 1988b) during 7.5 min. aData are
expressed as percentage ofcontrol samples (no drug added; mean±s.d.
of2 experiments) incubated for 7.5 min in medium B. In these control
cells ATP levels decreased to about40% compared to cells incubated in
complete growth medium.CYCLOSPORIN A AND VERAPAMIL 87
Table IV Effect ofcyclosporin A and verapamil on lactate formation
in 2780 cells
Lactate % ofcontrol
Drug (AM) A2780 2780AD
Verapamil 8 101± 2 135±3
Sandimmune 8 113± 7 99± 5
CyclosporinA 8 106±10 102±5
Cremophor EL 132,Ag/mla 117±11 101±2
Cell suspensions of about 2 x 106 cellsml' were incubated in
medium with 10% dialysed fetal calf serum (pH = 7.45) for 60 min at
37°C. Data are means±s.d. from three separate experiments, each
performed in triplicate. aConcentration present in 8ytM Sandimmune.
rubicin transport across the plasmamembrane, but apparent-
ly does not increase the cellular energy demand for its
interaction with P-glycoprotein. Evidence for a direct inter-
action of cyclosporin A with P-glycoprotein comes from the
observation that this drug competitively inhibits the binding
of a photoaffinity-labelled vinblastine analogue to P-glyco-
protein and of ATP-dependent vincristine binding to plasma
membranes of multidrug resistant cells with an apparent
inhibition constant of 0.1 IAM (Safa et al., 1989). The present
study suggests that there are differences between the mec-
hanism of interaction of cyclosporin A and verapamil with
P-glycoprotein.
Cyclosporin A is a hydrophobic peptide and has been
shown to partition into phospholipid vesicles and to increase
membrane fluidity (Haynes et al., 1985). We have also found,
using 1,6-diphenyl-1,3,5-hexatriene fluorescence polarisation,
that cyclosporin increased plasmamembrane fluidity of
A2780 and 2780AD cells (unpublished observations). Thus
by disrupting membrane architecture cyclosporin might affect
P-glycoprotein function (Arsenault et al., 1988). Alterna-
tively, inhibition of protein kinase C activity by cyclosporin
A (Walker et al., 1989) might interfere differently with the
energizing of P-glycoprotein.
This study was supported by a Bristol-Myers research grant and the
Dutch Cancer Society (IKA-VU 88-22).
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